Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Cancer Research |
Vol/bind | 16 |
Udgave nummer | 21 |
Sider (fra-til) | 5312-9 |
Antal sider | 8 |
ISSN | 1078-0432 |
DOI | |
Status | Udgivet - 1 nov. 2010 |
ID: 34133708